Eric Marandett on The Biologics Price Competition and Innovation Act

Eric Marandett was quoted in "A Riddle Wrapped in a Mystery Inside an Enigma" in IPPro Life Sciences, where he discusses the BPCIA and Amgen's decision to challenge the approval of Sandoz's Zarxio.  He explains that although the Federal Circuit dismissed some of Amgen's claims, they did agree that Sandoz could not market Zarxio for 180 days, giving Amgen a six-month exclusivity period.  He also says that the Federal Circuit panel being so divided makes a rehearing of the case a possibility.